Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Strata Skin Sciences (SSKN)
:SSKN
Holding SSKN?
Track your performance easily
SSKN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.51 - $6.00
Previous CloseN/A
Volume547.00
Average Volume (3M)8.29K
Market Cap
$12.35M
Enterprise Value$19.19M
Total Cash (Recent Filing)$3.93M
Total Debt (Recent Filing)$21.78M
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Mar 25, 2025EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.60
Shares Outstanding4,171,161
10 Day Avg. Volume4,397
30 Day Avg. Volume8,293
Standard Deviation0.16
R-Squared0.19
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.38
Price to Cash Flow (P/CF)-10.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.55
Enterprise Value/Revenue0.58
Enterprise Value/Gross Profit1.04
Enterprise Value/Ebitda-325.22
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Strata Skin Sciences News
PremiumCompany Announcements
Strata Skin Sciences Outlines Growth and Profitability Plans
PremiumCompany Announcements
STRATA Skin Sciences Achieves First Profit Since 2018PremiumCompany Announcements
Strata Skin Sciences Achieves Turnaround with Revenue Growth
PremiumCompany Announcements
Strata Skin Sciences Wins Legal Battle Over Claims
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SSKN FAQ
What was Strata Skin Sciences’s price range in the past 12 months?
Strata Skin Sciences lowest stock price was $2.51 and its highest was $6.00 in the past 12 months.
What is Strata Skin Sciences’s market cap?
Strata Skin Sciences’s market cap is $12.35M.
When is Strata Skin Sciences’s upcoming earnings report date?
Strata Skin Sciences’s upcoming earnings report date is Mar 25, 2025 which is in 66 days.
How were Strata Skin Sciences’s earnings last quarter?
Strata Skin Sciences released its earnings results on Nov 13, 2024. The company reported -$0.192 earnings per share for the quarter, beating the consensus estimate of -$0.445 by $0.253.
Is Strata Skin Sciences overvalued?
According to Wall Street analysts Strata Skin Sciences’s price is currently Overvalued.
Does Strata Skin Sciences pay dividends?
Strata Skin Sciences does not currently pay dividends.
What is Strata Skin Sciences’s EPS estimate?
Strata Skin Sciences’s EPS estimate is -0.4.
How many shares outstanding does Strata Skin Sciences have?
Strata Skin Sciences has 4,171,161 shares outstanding.
What happened to Strata Skin Sciences’s price movement after its last earnings report?
Strata Skin Sciences reported an EPS of -$0.192 in its last earnings report, beating expectations of -$0.445. Following the earnings report the stock price went down -7.463%.
Which hedge fund is a major shareholder of Strata Skin Sciences?
Currently, no hedge funds are holding shares in SSKN
---
Company Description
Strata Skin Sciences
STRATA Skin Sciences, Inc. is a medical technology company. The firm engages in the design, development, and commercializing of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations. It operates through the following segments: Dermatology Recurring Procedures; Dermatology Procedures Equipment; and Dermatology Imaging. The Dermatology Recurring Procedures segment offers XTRAC procedures. The Dermatology Procedures Equipment segment sells lasers and lamp products. The Dermatology Imaging segment comprises of the retail and usage of imaging devices. The company was founded by Dina Gutkowicz-Krusin in December 1989 and is headquartered in Horsham, PA.
---
SSKN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted several positive developments, such as improved gross margins, increased patient appointments through DTC initiatives, growth of TheraClearX devices, and a favorable litigation outcome. However, challenges remain with slight declines in total revenue and domestic recurring billings, and the impact of a sales tax audit accrual. Despite these challenges, the company's strategic efforts and strengthened financial position are paving the way for potential growth and profitability.Read More>---
Technical Analysis
Cutera
―
Evolus
―
Sonoma Pharmaceuticals
―
Helius Medical Technologies
―
T2 Biosystems
―
Viveve Medical
―
---